Paradoxically, the impact of these biomarkers on the overall survival of HER2-positive, basal-like, and normal-like breast carcinomas differs significantly when compared to luminal-type carcinomas (Figure 8). This evidence concerns the gene ERBB2 and breast carcinoma.